Trial Search Results
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 2009-2010 influenza vaccines in children and adults.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
- Biological: Fluzone® 2009-2010 Formula
- Biological: FluMist® 2009-2010 Formula
- Otherwise healthy, ambulatory children 8-17 year-old twins, adults 18-30 years old
(non-twin) or 70-100 year-old elderly non-twin adults.
- Willing to complete the informed consent process.
- Availability for follow-up for the planned duration of the study at least 28 days
- Acceptable medical history by medical history and vital signs.
- Prior off-study vaccination with the current seasonal TIV or LAIV in Fall 2009
- Allergy to egg or egg products, or to vaccine components, including gentamicin,
gelatin, arginine or MSG (for LAIV only), or thimerosal (TIV multidose vials only).
- Life-threatening reactions to previous influenza vaccinations
- Asthma or history of wheezing (for volunteers randomized to LAIV)
- Active systemic or serious concurrent illness, including febrile illness on the day of
- History of immunodeficiency (including HIV infection)
- Known or suspected impairment of immunologic function, including, but not limited to,
clinically significant liver disease, diabetes mellitus treated with insulin, moderate
to severe renal disease, or any other chronic disorder which, in the opinion of the
investigator, might jeopardize volunteer safety or compliance with the protocol.
- Blood pressure >150 systolic or >95 diastolic at first study visit
- Hospitalization in the past year for congestive heart failure or emphysema.
- Chronic Hepatitis B or C.
- Recent or current use of immunosuppressive medication, including systemic
glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in
all groups; inhaled steroid use is not permissible except for non-LAIV Group only).
Use of oral steroids (<20 mg prednisone-equivalent/day) may be acceptable for
volunteers 70-100 yrs of age after review by the investigator.
- Participants in close contact with anyone who has a severely weakened immune system
should not receive LAIV
- Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
such as breast cancer or prostate cancer with recurrence in the past year, and any
hematologic cancer such as leukemia).
- Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
of the investigator, might jeopardize volunteer safety or compliance with the
- History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
medical follow up or hospitalization during the preceding year
- Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be
reviewed by investigator to determine if this would affect the volunteer's safety.
- Receipt of blood or blood products within the past 6 months
- Medical or psychiatric condition or occupational responsibilities that preclude
participant compliance with the protocol
- Inactivated vaccine 14 days prior to vaccination
- Live, attenuated vaccine within 60 days of vaccination
- History of Guillain-Barré Syndrome
- Pregnant or lactating woman
- Use of investigational agents within 30 days prior to enrollment
- Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment
- Any condition which, in the opinion of the investigator, might interfere with
volunteer safety, study objectives or the ability of the participant to understand or
comply with the study protocol.
Ages Eligible for Study
8 Years - 100 Years
Genders Eligible for Study